July 8, 2010 – The Canadian Nuclear Safety Commission (CNSC) announced this week it has authorized the reactivation of the National Research Universal (NRU) reactor in Chalk River, Ontario, Canada. It is estimated that NRU will resume medical isotope production by the end of July, after being shut down in 2009 for several repairs.
Pulmonary embolism (PE) is generally treated with blood thinners, but a more aggressive treatment may be required for massive PE in hemodynamically compromised patients, said Ali Amin, M.D., a vascular surgeon at The Read Hospital and Medical Center in Reading, Pa.
Percutaneous mechanical thrombectomy (PMT) devices are increasingly being used to remove clots from coronary and peripheral vessels. They offer a faster treatment option than using traditional systemic thrombolytic (lytic) or catheter-directed thrombolysis (CDT).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
OSF HealthCare System, owned and operated by The Sisters of the Third Order of St. Francis, Peoria, Ill., is a seven-hospital enterprise serving 2.5 million patients throughout Illinois and Michigan.
Three companies made significant purchases and product introductions in May and June in efforts to gain a larger share of the interventional, cath lab device market. Combining IVUS, Therapeutic Devices
July 7, 2010 – Medical imaging company NovaRad recently expanded its distributor network by adding NXC Imaging to serve facilities in Wisconsin, South Dakota, North Dakota and parts of Illinois, Montana and Michigan. NXC Imaging will represent NovaRad’s products including:
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
July 7, 2010 – Vicor Technologies Inc. recently announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its PD2i algorithm and software. This would secure a claim for identifying, in conjunction with patient medical history and other tests, congestive heart failure patients at elevated risk of cardiac mortality.
July 6, 2010 – Maquet Cardiovascular LLC recently announced it will become the exclusive U.S. distributor of the InterGard family of vascular grafts. This will go into effect on Oct. 1, 2010, when its current distribution agreement with W.L. Gore & Associates expires.
July 6, 2010 – A new trial testing a new method of detecting ischemia in patients with coronary artery disease (CAD) has received its first patient enrollments. Cambridge Heart Inc.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
July 6, 2010 – The development of a new magnetic resonance imaging (MRI) technology, which may revolutionize the way medical conditions are diagnosed and treated, is to take a major step forward as a $10.6 million research center is established at the University of York.
July 6, 2010 – The government’s certification program for health information technology (HIT) will continue to evolve over time, according to a review of the recently released final rule for the temporary certification program, released last week.
July 6, 2010 – Ultrasound company SonoSite Inc. announced last week that it has completed its acquisition of privately held VisualSonics, a Toronto-based company focused on ultra high-frequency micro-ultrasound technology, for $67.9 million net of cash and debt.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
July 1, 2010 – Two medical companies say they will work with physicians to further investigate ways to manage genetic issues in antiplatelet therapy, after the U.S. Food and Drug Administration (FDA) recently released a warning about the efficacy of the antiplatelet drug clopidogrel (Plavix) on patients with certain genetic make-ups.
July 1, 2010 – The U.S. Food and Drug Administration (FDA) recently added a warning to the information on clopidogrel (Plavix), as a result of new information indicating that variations in genetic makeup can prevent the medication from reducing patients’ risk for heart attack and stroke.
July 1, 2010 – Clinical results have shown the Rheos System is successful in lowering blood pressure, CVRx Inc. announced this week at the European Society of Hypertension Meeting. The system is the first device designed to treat hypertension (high blood pressure) and is a future treatment option for the millions of people who cannot control their blood pressure with medications.